FAQs
1. Do all cancers require aggressive treatment like chemotherapy or surgery?
Not all cancers require the same treatment. Some are managed with less aggressive therapies, surveillance, or alternative options depending on the type and stage.
2. Can mobile phone use or exposure to Wi-Fi cause cancer?
Scientific evidence so far does not support a causative link between cell phones, Wi-Fi, and cancer. These devices emit low-frequency energy that does not damage DNA.
3. Can herbal remedies or superfoods cure cancer?
There is no scientific evidence that herbal products or so-called “superfoods” cure cancer. Relying solely on them can prove dangerous.
Reference
1. Gerstberger, S., Jiang, Q., & Ganesh, K. (2023). Metastasis. Cell, 186(8), 1564-1579.
2. Jiang, Z., Zeng, G., Dai, H., et al. (2025). Global, regional and National burden of liver cancer 1990–2021: a systematic analysis of the global burden of disease study 2021. BMC Public Health, 25(1), 931.
3. Palshof, F. K., Mørch, L. S., Køster, B., et al. (2024). Non-preventable cases of breast, prostate, lung, and colorectal cancer in 2050 in an elimination scenario of modifiable risk factors. Scientific Reports, 14(1), 8577.
4. Rahner, N., & Steinke, V. (2008). Hereditary cancer syndromes. Deutsches Ärzteblatt International, 105(41), 706.
5. Parsa, N. (2012). Environmental factors inducing human cancers. Iranian journal of public health, 41(11), 1.
6. Fouad, Y. A., & Aanei, C. (2017). Revisiting the hallmarks of cancer. American journal of cancer research, 7(5), 1016.
7. Barnum, K. J., & O’Connell, M. J. (2014). Cell cycle regulation by checkpoints. In Cell cycle control: mechanisms and protocols (pp. 29-40). New York, NY: Springer New York.
8. Elmore, S. (2007). Apoptosis: a review of programmed cell death. Toxicologic pathology, 35(4), 495-516.
9. Coskun, V., & Luskin, M. B. (2002). Intrinsic and extrinsic regulation of the proliferation and differentiation of cells in the rodent rostral migratory stream. Journal of neuroscience research, 69(6), 795-802.
10. Bich, L., Pradeu, T., & Moreau, J. F. (2019). Understanding multicellularity: the functional organization of the intercellular space. Frontiers in Physiology, 10, 1170.
11. Kontomanolis, E. N., Koutras, A., Syllaios, A., et al. (2020). Role of oncogenes and tumor-suppressor genes in carcinogenesis: a review. Anticancer research, 40(11), 6009-6015.
12. Lee, E. Y., & Muller, W. J. (2010). Oncogenes and tumor suppressor genes. Cold Spring Harbor perspectives in biology, 2(10), a003236.
13. Lahtz, C., & Pfeifer, G. P. (2011). Epigenetic changes of DNA repair genes in cancer. Journal of molecular cell biology, 3(1), 51-58.
14. Kanwal, R., & Gupta, S. (2012). Epigenetic modifications in cancer. Clinical genetics, 81(4), 303-311.
15. Loeb, L. A., & Harris, C. C. (2008). Advances in chemical carcinogenesis: a historical review and prospective. Cancer research, 68(17), 6863.
16. Petrick, J. L., Campbell, P. T., Koshiol, J., et al. (2018). Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project. British journal of cancer, 118(7), 1005-1012.
17. Rivas, M., Rojas, E., Araya, M. C., et al. (2015). Ultraviolet light exposure, skin cancer risk and vitamin D production. Oncology letters, 10(4), 2259-2264.
18. Moore, P. S., & Chang, Y. (2010). Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nature reviews cancer, 10(12), 878-889.
19. Polk, D. B., & Peek Jr, R. M. (2010). Helicobacter pylori: gastric cancer and beyond. Nature reviews cancer, 10(6), 403-414.
20. Correia da Costa, J. M., Vale, N., Gouveia, M. J., et al. (2014). Schistosome and liver fluke derived catechol-estrogens and helminth associated cancers. Frontiers in genetics, 5, 444.
21. Hawsawi, Y. M., Al‐Numair, N. S., Sobahy, T. M., et al. (2019). The role of BRCA1/2 in hereditary and familial breast and ovarian cancers. Molecular genetics & genomic medicine, 7(9), e879.
22. Rustgi, A. K. (2007). The genetics of hereditary colon cancer. Genes & development, 21(20), 2525-2538.
23. Sharman, R., Harris, Z., Ernst, B., et al. (2024). Lifestyle factors and cancer: a narrative review. Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 8(2), 166-183.
24. Thandra, K. C., Barsouk, A., Saginala, K., et al. (2021). Epidemiology of lung cancer. Contemporary Oncology/Współczesna Onkologia, 25(1), 45-52.
25. Sun, Y. S., Zhao, Z., Yang, Z. N., et al. (2017). Risk factors and preventions of breast cancer. International journal of biological sciences, 13(11), 1387.
26. Wang, F., Shu, X., Meszoely, I., et al. (2019). Overall mortality after diagnosis of breast cancer in men vs women. JAMA oncology, 5(11), 1589-1596.
27. Sullivan, B. A., Noujaim, M., & Roper, J. (2022). Cause, epidemiology, and histology of polyps and pathways to colorectal cancer. Gastrointestinal Endoscopy Clinics, 32(2), 177-194.
28. Bretthauer, M., Løberg, M., Wieszczy, P., et al. (2022). Effect of colonoscopy screening on risks of colorectal cancer and related death. New England Journal of Medicine, 387(17), 1547-1556.
29. Stangelberger, A., Waldert, M., & Djavan, B. (2008). Prostate cancer in elderly men. Reviews in urology, 10(2), 111.
30. Chennamadhavuni, A., Lyengar, V., Mukkamalla, S. K. R., et. al. (2023). In StatPearls [Internet]. StatPearls Publishing.
31. Jamil, A., & Mukkamalla, S. K. R. (2023). Lymphoma. In StatPearls [Internet]. StatPearls Publishing.
32. Sia, D., Villanueva, A., Friedman, S. L., et al. (2017). Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology, 152(4), 745-761.
33. Vincent, A., Herman, J., Schulick, R., et al. (2011). Pancreatic cancer. The lancet, 378(9791), 607-620.
34. Matulonis, U. A., Sood, A. K., Fallowfield, L., et al. (2016). Ovarian cancer. Nature reviews Disease primers, 2(1), 1-22.
35. Quail, D. F., & Joyce, J. A. (2017). The microenvironmental landscape of brain tumors. Cancer cell, 31(3), 326-341.
36. Apalla, Z., Nashan, D., Weller, R. B., et al. (2017). Skin cancer: epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches. Dermatology and therapy, 7(Suppl 1), 5-19.
37. Harper, D. M., & DeMars, L. R. (2017). HPV vaccines–a review of the first decade. Gynecologic oncology, 146(1), 196-204.
38. Pattyn, J., Hendrickx, G., Vorsters, A., et al. (2021). Hepatitis B vaccines. The Journal of infectious diseases, 224(Supplement_4), S343-S351.
39. Ribli, D., Horváth, A., Unger, Z., et al. (2018). Detecting and classifying lesions in mammograms with deep learning. Scientific reports, 8(1), 4165.
40. Young, P. E., & Womeldorph, C. M. (2013). Colonoscopy for colorectal cancer screening. Journal of Cancer, 4(3), 217.
41. Pulumati, A., Pulumati, A., Dwarakanath, B. S., et al. (2023). Technological advancements in cancer diagnostics: Improvements and limitations. Cancer Reports, 6(2), e1764.
42. Bi, W. L., Hosny, A., Schabath, M. B., et al. (2019). Artificial intelligence in cancer imaging: clinical challenges and applications. CA: a cancer journal for clinicians, 69(2), 127-157.
43. Chakraborty, S., Hosen, M. I., Ahmed, M., et al. (2018). Onco‐multi‐OMICS approach: a new frontier in cancer research. BioMed research international, 2018(1), 9836256.
44. Friedman, A. A., Letai, A., Fisher, D. E., et al. (2015). Precision medicine for cancer with next-generation functional diagnostics. Nature Reviews Cancer, 15(12), 747-756.
45. Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., et al. (2012). Immunotherapy of cancer in 2012. CA: a cancer journal for clinicians, 62(5), 309-335.
46. Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: current limitations and potential strategies. Blood cancer journal, 11(4), 69.
47. Webb, E. S., Liu, P., Baleeiro, R., et al. (2017). Immune checkpoint inhibitors in cancer therapy. Journal of biomedical research, 32(5), 317.
48. Scott, A. M., Allison, J. P., & Wolchok, J. D. (2012). Monoclonal antibodies in cancer therapy. Cancer immunity, 12(1), 14.
49. Russell, L., & Peng, K. W. (2018). The emerging role of oncolytic virus therapy against cancer. Chinese clinical oncology, 7(2), 16.
50. Virgolini, I., Decristoforo, C., Haug, A., et al. (2018). Current status of theranostics in prostate cancer. European journal of nuclear medicine and molecular imaging, 45(3), 471-495.
51. Shi, J., Kantoff, P. W., Wooster, R., et al. (2017). Cancer nanomedicine: progress, challenges and opportunities. Nature reviews cancer, 17(1), 20-37.
52. Edelman, L. B., Eddy, J. A., & Price, N. D. (2010). In silico models of cancer. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2(4), 438-459.
53. Tuveson, D., & Clevers, H. (2019). Cancer modeling meets human organoid technology. Science, 364(6444), 952-955.